alexa DPP4 Inhibition in Human Kidney Proximal Tubular Cells - Renoprotection in Diabetic Nephropathy?

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

DPP4 Inhibition in Human Kidney Proximal Tubular Cells - Renoprotection in Diabetic Nephropathy?

The incretin system has been the target of newer glucose lowering medications used in the treatment of Type 2 diabetes mellitus. Specific drugs include the glucagon-like peptide 1 (GLP-1) analogues and dipeptidyl peptidase 4 (DPP4) inhibitors. The incretin hormones consist of GLP-1 and gastrointestinal peptide which are released from the gut in response to a meal. GLP-1 promotes insulin release and inhibits glucagon secretion in a glucose dependent manner which results in the regulation of postprandial glucose excursions. Endogenous GLP-1 hormones have a very short half life as they are rapidly degraded by DPP4 where GLP-1 (7-36) amide is cleaved to GLP-1 (9-36) amide, which is the major circulating form. Hence DPP4 inhibitors exert their hypoglycaemic action by raising endogenous levels of GLP-1

Citation:Panchapakesan U, Gross S, Komala MG, Pegg K, Pollock CA (2013) DPP4 Inhibition in Human Kidney Proximal Tubular Cells - Renoprotection in Diabetic Nephropathy? J Diabetes Metab S9:007. doi: 10.4172/2155-6156.S9-007

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger